intoxicant.wiki2catechol4school
Serotonin receptor agonist · Serotonin 5-HT2A receptor agonist · Serotonergic psychedelic · Hallucinogen

MSP-1014

Original Wikipedia articleen.wikipedia.org/wiki/MSP-1014 revision used (24 October 2026)

Why a "revision used" link? Anyone can edit Wikipedia at any time, so the article you open today may not say what it said when we read it. This link opens the exact version we read on 24 October 2026, frozen as it was. It is the only way to check that every quote on this page matches its source word for word. Newer versions may correct or change things. When we re-check this page against a newer version, the edit log records it. How we cite

Part of the metabolic pathway of MSP-1014. See the timeline on the metabolic highway.

Overview

MSP-1014 is a serotonergic psychedelic which is under development for the treatment of major depressive disorder, other depressive disorders, and anxiety disorders.[1–6] WP

It is a prodrug of psilocin similarly to psilocybin, and hence acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT2A receptor. The animal pharmacodynamics and pharmacokinetics of MSP-1014 have been studied, demonstrating a shorter plasma half-life compared to psilocybin.[1][3][4][6][7] WP

The drug is under development by Mindset Pharma and Otsuka America Pharmaceutical. As of January 2024, it is in phase 2 clinical trials for major depressive disorder and is in the preclinical stage of development for anxiety disorders and other depressive disorders. The chemical structure of MSP-1014 does not yet seem to have been disclosed. However, Mindset Pharma patented psilocin derivatives and prodrugs in 2022.[1–4][8] WP

Drug class

Serotonin receptor agonist Serotonin 5-HT2A receptor agonist Serotonergic psychedelic Hallucinogen WP

From the Wikipedia article's infobox.

Chemistry

Awaiting sourceFormula, structure and identifiers from PubChem.

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

Awaiting sourceChecked against PsychonautWiki and TripSit as each pull runs. This box is replaced as soon as a source has data.

User reports

Erowid erowid.org

Listings
Awaiting sourceExperience Vault listing and report categories.
Top stories
Awaiting sourceShort summaries of the most-read reports, each linked, saying only what the report says.

Bluelight bluelight.org

Listings
Awaiting sourceTrip report threads and this substance's discussion forum.
Top stories
Awaiting sourceShort summaries of the most-read reports, each linked, saying only what the report says.

Reddit reddit.com

Listings
Awaiting sourceTrip report posts and the relevant subreddits.
Top stories
Awaiting sourceShort summaries of the most-read reports, each linked, saying only what the report says.

Pop culture

No references added yet.

Add a reference

Registered users can add songs, films, books, shows, games and art about this substance. Link a source that names the substance, such as the work's Wikipedia article, a review or an interview, not only the work itself. Entries are voted on and moderated like every other value on this page.

Opens when accounts launch.

Sources

  1. Journal / agency MSP 1014. 9 January 2024
  2. Other Delving into the Latest Updates on MSP-1014 with Synapse. 26 October 2024
  3. Journal / agency Palfreyman MG, Varty GB, Stang E, Boltaev U, Avery K, Nivorozhkin A. Modification of natural tryptamines for the treatment of neuropsychiatric diseases. J Psychopharmacol. December 2025. doi:10.1177/02698811251368362 · PMID 41045211
  4. Other Mindset Pharma Receives Approval for Phase II Clinical Trial Evaluating MSP-1014 for the Treatment of Major Depressive Disorder. 22 June 2023
  5. Other Mindset Pharma. Mindset Pharma Presents Poster at Neuroscience 2022 Highlighting Preclinical Data on MSP-1014, its Psilocybin-like Lead Drug Candidate. 14 November 2022
  6. Other Araujo JA, Higgins GA, de Lannoy IA, Dean I, Atkinson J, Lanthier J, Slassi M. (2022 November 13). 147.05 / JJ5 - The preclinical safety, behavioural and pharmacokinetics properties of MSP-1014, a novel prodrug of psilocin. Neuroscience 2022
  7. Journal / agency Dodd S, Norman TR, Eyre HA, Stahl SM, Phillips A, Carvalho AF, Berk M. Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy. CNS Spectrums. July 2022. doi:10.1017/S1092852922000888 · PMID 35811423
  8. Other Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0). Each value links to the exact revision it came from.